NICE
NICE and EuroQol Research Foundation to Support New EQ-5D-5L Valuation Study
24 October 2019
As indicated in its recent statement, NICE supports a new valuation study to generate a value set for the EQ-5D-5L. We welcome this announcement. As indicated…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden.…
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
20 March 2019
Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical…
End of Life Treatments, Societal Values, and ‘Overall’ Preference
12 February 2019
OHE’s Koonal Shah gave a presentation on societal values and the provision of end of life treatments at a Manchester Centre for Health Economics seminar.
OHE Response to Public Consultation on NICE Principles
7 February 2019
OHE has submitted a response to the public consultation on updating the principles that guide the development of NICE guidance and standards.
Generating Preference-based Values for the EQ-5D-Y to Support Its Use in HTA
31 January 2019
OHE’s Koonal Shah and Oliver Rivero-Arias presented at a NICE Technical Forum on the topic of valuing health in children and adolescents.
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.
NICE Recommendation Highlights Role of Social Value Judgements
9 August 2018
This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma. The…
Opportunity Costs of New Health Care Technologies: A Research Agenda
8 August 2018
A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.